Purdue continues OxyContin patent battle
10-10-2017
Savushkin / iStockphoto.com
The US Court of Appeals for the Federal Circuit has affirmed a decision by the Patent Trial and Appeal Board (PTAB) which found that two patent applications by Purdue Pharma were unpatentable.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Purdue Pharma, patent, unpatentable, Recro Technology, PTAB,
